# To Evaluate the Renal Protective Effects and Safety of 'Fimasartan and Atorvastatin' or 'Fimasartan, Atorvastatin and Ezetimibe'.

> **NCT07685054** · — · NOT_YET_RECRUITING · sponsor: **Boryung Pharmaceutical Co., Ltd** · enrollment: 12700 (estimated)

## Conditions studied

- Essential Hypertension
- Primary Hypercholesterolemia

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07685054
- **Lead sponsor:** Boryung Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-01
- **Primary completion:** 2029-08-15
- **Final completion:** 2029-08-15
- **Target enrollment:** 12700 (ESTIMATED)
- **Last updated:** 2026-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07685054

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07685054, "To Evaluate the Renal Protective Effects and Safety of 'Fimasartan and Atorvastatin' or 'Fimasartan, Atorvastatin and Ezetimibe'.". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07685054. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*